Healthcare Startup Medulance Pockets $3 Mn From Alkemi Growth Capital, Others

Emergency healthcare services provider Medulance has raised $3 Mn (INR 25 Cr) in a Series A funding round led by Alkemi Growth Capital, with participation from Dexter Capital, Aman Gupta and Namita Thapar.

The startup plans to deploy the funds to scale up its presence across India while focusing on emergency management technology to better handle large-scale service execution challenges.

This includes reducing emergency call answering and response times in over 500 cities across India.

The startup seeks to impact regions such as India, where the incidence of acute life-threatening diseases is high, by extending its services to Tier 2 and Tier 3 cities. The objective is to provide consistent and high-quality emergency healthcare services nationwide.

Medulance plans to expand to over 1,000 cities in the next 15-18 months 

while prioritising patient safety and quality of care in every region. It also aims to establish public-private partnerships to expand its services into more states.

Medulance claims to have secured the funding after operating as a profitable bootstrapped company for six years.

Pranav Bajaj, cofounder and CEO of Medulance, said, “…This funding marks an important milestone for Medulance. With the support of our investors, we are poised to scale our operations and further elevate the standards of emergency healthcare across India.”

Ravjot Singh Arora, cofounder and COO of Medulance, highlighted that in the last six years, Medulance has grown its fleet to 10,000 ambulances, covering over 500 cities nationwide. It further claims to have reduced the dispatch time for emergency ambulances from 5 to just 2 minutes.

“Medulance has also brought the response time in cities like Delhi from 45 minutes to 11 minutes. Through this capital, Medulance would leverage the latest technology including 5G  and smart remote monitoring via its smart ambulances to create a 360-degree ecosystem by partnering with corporates, governments, and insurance companies,” he added.

Alka Goel, founder of Alkemi Growth Capital, said, “The infusion of capital into Medulance will enable it to expand its fleet, enhance its technology infrastructure, and improve its response times. This investment will also support the company in recruiting and training qualified medical professionals to ensure the highest standards of patient care.”

Aman Gupta, cofounder, boAt, said, “Investing in an emergency medical services innovator like Medulance isn’t just about capital—it’s about empowering communities, saving lives, and shaping a healthier future.”

Anuradha Agrawal, general partner at Dexter Ventures, said, “Having built and scaled Medulance profitably while being bootstrapped in a market filled with large players with strong footing, coupled with a strong clientele across govt bodies, corporate MNCs, etc is a strong testament of Pranav and Ravjot’s perseverance and execution skills.”

Founded in 2017 by Bajaj and Arora, Medulance has revolutionised emergency medical services in India since its inception. From ambulances to 5G smart medical clinics, the company provides holistic solutions for corporate and public healthcare needs. 

Recently, Medulance introduced India’s first 5G-enabled ‘Smart Medical Room’ in Gurgaon, raising the bar for corporate wellness with advanced diagnostics and telemedicine integration. Additionally, the company has offered medical assistance at prominent events such as the IPL and ICC Men’s Cricket World Cup.

Meanwhile, earlier this month, the Union Health Ministry launched the myCGHS app, to enhance access to electronic health records, information, and resources for beneficiaries of the central government health scheme (CGHS).

In addition to this, industry leaders such as Apollo Hospitals, Max Healthcare, and health-focused startups like Healthify are harnessing the power of GenAI to elevate healthcare standards in the country or exploring potential avenues for its application. Moreover, global pharmaceutical giants like Pfizer, Novartis, and Merck are already using GenAI for drug discovery on a global scale. 

While GenAI adoption in the Indian healthcare sector primarily revolves around chatbots currently, Indian startups are progressively enhancing their efforts to keep pace with their international counterparts.

Note: We at Inc42 take our ethics very seriously. More information about it can be found here.